Mayo Clinic | Strategic Alliance Partners

March 07, 2023

Daniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.

March 06, 2023

Daniel H. Ahn, DO, discusses the importance of drug toxicity when selecting between first-line immune checkpoint inhibitor–based regimens in hepatocellular carcinoma.

March 06, 2023

Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.

March 06, 2023

Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.

March 03, 2023

Medical oncologist Tian Zhang, MD, outlines the remaining unmet needs and knowledge gaps surrounding imaging of prostate cancer.

March 03, 2023

Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.

February 27, 2023

Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.

February 27, 2023

Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.

February 20, 2023

Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.

February 20, 2023

After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.

February 17, 2023

The PARP inhibitor rucaparib improved median radiographic progression-free survival by 4.8 months compared with physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer.

February 17, 2023

Checkpoint inhibitor–based salvage regimens significantly reduced the likelihood that patients with relapsed/refractory classic Hodgkin lymphoma undergoing transplant would need further salvage therapy vs conventional salvage regimens.

February 16, 2023

Tufia C. Haddad, MD, discusses key results from a prospective trial on adjuvant anastrozole in estrogen receptor–positive, HER2-negative breast cancer.

February 16, 2023

A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.

February 16, 2023

Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.

February 14, 2023

Treatment with brexucabtagene autoleucel in the standard-of-care relapsed/refractory mantle cell lymphoma setting provided an efficacy and safety profile consistent with data reported in the phase 2 ZUMA-2 trial.

February 10, 2023

Daniel Walden, MD, discusses the association of low expression of RNA of wild-type homologous recombination genes and survival in colorectal cancer.

February 09, 2023

Experts in metastatic colorectal cancer management highlight the role of molecular testing and testing modalities available in the academic and community settings.

February 03, 2023

Judy C. Boughey, MD, discusses the significance of results from the phase 2 ACOSOG Z11102 trial evaluating breast conserving therapy in multiple ipsilateral breast cancer. 

February 03, 2023

The MOUNTAINEER-03 trial is designed to evaluate the efficacy of tucatinib and trastuzumab plus modified leucovorin calcium, fluorouracil, and oxaliplatin, compared with standard-of-care, first-line therapy for metastatic HER2-positive colorectal cancer.